34.92
-0.99 (-2.76%)
| 前收盘价格 | 35.91 |
| 收盘价格 | 35.50 |
| 成交量 | 1,134,404 |
| 平均成交量 (3个月) | 1,432,817 |
| 市值 | 5,513,762,816 |
| 预期市盈率 (P/E Forward) | 90.91 |
| 价格/销量 (P/S) | 6.65 |
| 股市价格/股市净资产 (P/B) | 8.72 |
| 52周波幅 | |
| 利润日期 | 19 Feb 2025 - 24 Feb 2025 |
| 营业毛利率 | -44.96% |
| 营业利益率 (TTM) | -29.34% |
| 稀释每股收益 (EPS TTM) | -2.52 |
| 季度收入增长率 (YOY) | 19.60% |
| 总债务/股东权益 (D/E MRQ) | 753.05% |
| 流动比率 (MRQ) | 7.61 |
| 营业现金流 (OCF TTM) | -345.98 M |
| 杠杆自由现金流 (LFCF TTM) | -211.82 M |
| 资产报酬率 (ROA TTM) | -7.58% |
| 股东权益报酬率 (ROE TTM) | -105.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Ionis Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.60 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.78% |
| 机构持股比例 | 98.22% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tweedy, Browne Co Llc | 30 Sep 2024 | 3,454,676 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 77.00 (Wells Fargo, 120.50%) | 购买 |
| 中 | 63.50 (81.84%) | |
| 低 | 60.00 (Needham, 71.82%) | 购买 |
| 平均值 | 66.00 (89.00%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 37.35 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 20 Dec 2024 | 60.00 (71.82%) | 购买 | 35.63 |
| 07 Nov 2024 | 60.00 (71.82%) | 购买 | 38.46 | |
| Piper Sandler | 14 Nov 2024 | 62.00 (77.55%) | 购买 | 37.23 |
| Wells Fargo | 07 Nov 2024 | 77.00 (120.50%) | 购买 | 38.46 |
| Guggenheim | 09 Oct 2024 | 65.00 (86.14%) | 购买 | 38.06 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HAYDEN MICHAEL R | 36.08 | - | 5,000 | 180,400 |
| 累积净数量 | 5,000 | |||
| 累积净值 ($) | 180,400 | |||
| 累积平均购买 ($) | 36.08 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HAYDEN MICHAEL R | 董事 | 23 Dec 2024 | 买 (+) | 5,000 | 36.08 | 180,400 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合